Clearing Amyloid Provides Alzheimer’s Benefit, But With Risks That Need Careful Management
Sponsors Plan Extensive Education About Safety
Eisai/Biogen’s lecanemab showed that reducing amyloid can slow Alzheimer’s disease progression, but prescribers will have to weigh the potential benefit versus safety risks on a patient-by-patient basis.
